KR970706796A - 약학 조성물(pharmaceutical compositions) - Google Patents

약학 조성물(pharmaceutical compositions)

Info

Publication number
KR970706796A
KR970706796A KR1019970702752A KR19970702752A KR970706796A KR 970706796 A KR970706796 A KR 970706796A KR 1019970702752 A KR1019970702752 A KR 1019970702752A KR 19970702752 A KR19970702752 A KR 19970702752A KR 970706796 A KR970706796 A KR 970706796A
Authority
KR
South Korea
Prior art keywords
composition
fatty acid
unsaturated fatty
alcohol
topical administration
Prior art date
Application number
KR1019970702752A
Other languages
English (en)
Other versions
KR100434682B1 (ko
Inventor
마틴 잭만
수-핑 폽
프리드리히 리히터
프리쯔 쉬무크
Original Assignee
한스 루돌프 하우스; 안토니오 나톨리
노바르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed by 한스 루돌프 하우스; 안토니오 나톨리, 노바르티스 아게 filed Critical 한스 루돌프 하우스; 안토니오 나톨리
Publication of KR970706796A publication Critical patent/KR970706796A/ko
Application granted granted Critical
Publication of KR100434682B1 publication Critical patent/KR100434682B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 FK506류 화합물; 이 화합물의 용매로서 탄소원자수 8 이하인 생리학적 허용성 알칸디올, 에테르디올 또는 디에테르 알콜; 불포화 지방산 알콜 및 물을 함유하는 유탁액 형태의 국소 투여용 조성물에 관한 것이다.
제 2목적으로서, 본 발명은 매크롤라이드를 현탁상태로 함유하는 국소 투여용 약학 조성물을 제공한다.
제 3목적으로서, 본 발명은 약학 조성물중에 매크롤라이드를 안정화시키기 위해 불포화 지방산 알콜을 사용하는 방법을 제공한다.

Description

약학 조성물(PHARMACEUTICAL COMPOSITIONS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. FK506류의 화합물; 이 화합물의 용매로서 탄소원자수 8 이하의 생리학적 허용성 알칸디올, 에테르 디올 또는 디에테르 알콜; 불포화 지방산 알콜 및 물을 함유하는 유탁액 형태의 국소 투여용 조성물.
  2. 제1항에 있어서, FK506류 화합물이 아스코마이신, 33-에피-클로로-33-데스옥시아스코마이신 또는 FK506인 국소 투여용 조성물.
  3. 제1항 또는 제2항에 있어서, 용매가 헥실렌 글리콜인 것을 특징으로 하는 국소 투여용 조성물.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 불포화 지방산 알콜이 올레일 알콜인 것을 특징으로 하는 국소 투여용 조성물.
  5. 매크롤라이드를 현탁 상태로 함유하는 국소 투여용 약학 조성물.
  6. 제 5항에 있어서, 매크롤라이드가 아스코마이신, 라파마이신 또는 FK506류 화합물인 것을 특징으로 하는 조성물.
  7. 제6항에 있어서, 매크롤라이드가 아스코마이신, 33-에피-클로로-33-데스옥시아스코마이신 또는 FK506인 것을 특징으로 하는 조성물.
  8. 염중성 또는 과중식성 피부 질환이나 면역학적-매개 질환의 피부 증상의 치료가 필요한 환자의 피부에 제1항 내지 제7항 중 어느 한 항의 국소 투여용 조성물을 투여하는 것으로 구성되는, 상기 질환을 치료하는 방법.
  9. 약학 조성물중에 매크롤라이드를 안정화시키기 위해 불포화 지방산 알콜을 사용하는 방법.
  10. 매크롤라이드와 불포화 지방산 알콜을 혼합하는 것으로 구성되는, 약학 조성물중에 매크롤라이드를 안정화시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702752A 1994-10-26 1995-10-26 약학조성물 KR100434682B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9421612.4 1994-10-26
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GB9422306.2 1994-11-04
GB9503553.1 1995-02-22
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds

Publications (2)

Publication Number Publication Date
KR970706796A true KR970706796A (ko) 1997-12-01
KR100434682B1 KR100434682B1 (ko) 2004-08-18

Family

ID=27267447

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702752A KR100434682B1 (ko) 1994-10-26 1995-10-26 약학조성물

Country Status (26)

Country Link
US (1) US6352998B2 (ko)
EP (2) EP0786986B1 (ko)
JP (3) JP4155593B2 (ko)
KR (1) KR100434682B1 (ko)
CN (2) CN1089233C (ko)
AT (2) ATE214593T1 (ko)
AU (1) AU714254B2 (ko)
BR (1) BR9509530A (ko)
CA (1) CA2200966C (ko)
CY (1) CY2211B1 (ko)
CZ (1) CZ289773B6 (ko)
DE (3) DE69525957T2 (ko)
DK (2) DK1147766T3 (ko)
ES (2) ES2243369T3 (ko)
FI (2) FI119754B (ko)
GB (1) GB2308546B (ko)
HK (1) HK1053611A1 (ko)
HU (1) HU223840B1 (ko)
MX (1) MX9702699A (ko)
NO (2) NO316963B1 (ko)
NZ (2) NZ295170A (ko)
PL (1) PL184750B1 (ko)
PT (2) PT786986E (ko)
SI (1) SI0786986T1 (ko)
SK (1) SK284591B6 (ko)
WO (1) WO1996013249A1 (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
CA2326222C (en) 1998-04-27 2008-09-23 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
WO2002065947A2 (de) * 2001-02-16 2002-08-29 Abbott Laboratories Vascular Enterprises Limited Implante mit fk506 zur restenosebehandlung und -prophylaxe
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US20060115522A1 (en) * 2003-02-17 2006-06-01 Cipla Ltd Pharmaceutical composition
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
AU2004258745A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
RU2375044C2 (ru) * 2004-04-08 2009-12-10 Новартис Аг Пимекролимусная пенная композиция, включающая гексиленгликоль, необязательно олеиловый спирт, диметилизосорбид и/или триглицериды со средними цепями
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
WO2013111817A1 (ja) * 2012-01-25 2013-08-01 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
EP2948134B1 (en) * 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
CN109069418A (zh) * 2016-04-04 2018-12-21 药品配送方案有限公司 包含他克莫司的局部组合物
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
PH26083A (en) 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
JP2799208B2 (ja) 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
JPH05504956A (ja) 1990-03-12 1993-07-29 藤沢薬品工業株式会社 トリシクロ化合物
EP0533930A1 (en) 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
ATE150304T1 (de) * 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
DE10199039I2 (de) 1993-10-22 2008-08-07 Hexal Ag Ind 25 Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator

Also Published As

Publication number Publication date
CZ123297A3 (en) 1997-08-13
JPH10508588A (ja) 1998-08-25
PL184750B1 (pl) 2002-12-31
NO2004005I1 (no) 2004-09-20
CN1162259A (zh) 1997-10-15
MX9702699A (es) 1997-06-28
JP4155593B2 (ja) 2008-09-24
NO971951D0 (no) 1997-04-25
DE69534306D1 (de) 2005-08-11
DE69534306T2 (de) 2006-04-27
KR100434682B1 (ko) 2004-08-18
CZ289773B6 (cs) 2002-04-17
GB2308546A (en) 1997-07-02
EP1147766B1 (en) 2005-07-06
CY2211B1 (en) 2002-11-08
SI0786986T1 (en) 2002-06-30
ES2243369T3 (es) 2005-12-01
EP0786986B1 (en) 2002-03-20
ES2173978T3 (es) 2002-11-01
SK52097A3 (en) 1997-09-10
FI971018A (fi) 1997-04-18
PT1147766E (pt) 2005-11-30
PL319599A1 (en) 1997-08-18
FI119755B (fi) 2009-03-13
DE69525957T2 (de) 2002-11-14
SK284591B6 (sk) 2005-07-01
BR9509530A (pt) 1997-10-14
CA2200966A1 (en) 1996-05-09
US20010031769A1 (en) 2001-10-18
CN1089233C (zh) 2002-08-21
NZ331824A (en) 2000-01-28
FI971018A0 (fi) 1997-03-11
GB9707484D0 (en) 1997-05-28
HK1053611A1 (en) 2003-10-31
NO316963B1 (no) 2004-07-12
AU714254B2 (en) 1999-12-23
JP2012131827A (ja) 2012-07-12
JP5599422B2 (ja) 2014-10-01
GB2308546B (en) 1999-06-02
FI119754B (fi) 2009-03-13
EP0786986A1 (en) 1997-08-06
ATE214593T1 (de) 2002-04-15
CN100335063C (zh) 2007-09-05
HU223840B1 (hu) 2005-02-28
WO1996013249A1 (en) 1996-05-09
JP2007145860A (ja) 2007-06-14
US6352998B2 (en) 2002-03-05
NO971951L (no) 1997-04-25
NO2004005I2 (no) 2007-06-11
DE19581804T1 (de) 1998-01-22
DK1147766T3 (da) 2005-08-29
HUT77140A (hu) 1998-03-02
NZ295170A (en) 1999-02-25
AU3845195A (en) 1996-05-23
CA2200966C (en) 2006-12-19
EP1147766A2 (en) 2001-10-24
FI20071025A (fi) 2007-12-28
EP1147766A3 (en) 2001-10-31
DK0786986T3 (da) 2002-04-29
CN1401325A (zh) 2003-03-12
ATE299017T1 (de) 2005-07-15
PT786986E (pt) 2002-07-31
DE69525957D1 (de) 2002-04-25

Similar Documents

Publication Publication Date Title
KR970706796A (ko) 약학 조성물(pharmaceutical compositions)
EP1153595B1 (en) Clear aqueous ceramide composition
KR920021139A (ko) 약학 조성물
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
US5728690A (en) Clear non-alcoholic hydrocortisone solutions
JP2660198B2 (ja) コルチコステロイド含有外用クリーム製剤
JPH06502161A (ja) レチノイド浸透作用エンハンサーを含む局所用組成物
JPH0570609B2 (ko)
JPS5517310A (en) Preparation of drug for external use
DE2708419B2 (de) Verwendung von 1,2-Butandiol-lmethyläther als Lösungsmittel für pharmazeutische Injektionslösungen
JP2688914B2 (ja) 皮膚外用剤
RU2107492C1 (ru) Мазь для лечения тромбофлебита
JP2006298862A (ja) 乳化組成物および皮膚外用剤
RU97108135A (ru) Фармацевтические составы
JPH08268870A (ja) 皮膚外用剤
GB9421612D0 (en) Organic compounds
JPH04312510A (ja) 化粧料組成物

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130502

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20140508

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20150430

Year of fee payment: 12

EXPY Expiration of term